Jeffrey Farrow

Jeffrey Farrow

Chief Financial Officer

Mr. Farrow joined GBT in April 2016 as chief financial officer with expertise in leading finance, risk management and investor relations for several public biotech companies as they evolved from discovery and development to commercial stage. Mr. Farrow previously served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company acquired by AstraZeneca. Prior to ZS Pharma, he served as chief financial officer at Hyperion Therapeutics, Inc., where he led the company’s initial public offering and follow-on offering and was part of the team responsible for the successful regulatory approval and commercial launch of RAVICTI® for the treatment of urea cycle disorders. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, Inc., a drug discovery and development company acquired by Evotec AG. Earlier in his career, Mr. Farrow worked in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton. He is a certified public accountant (inactive).